ChemoCentryx, Inc. (CCXI): Price and Financial Metrics
CCXI Price/Volume Stats
| Current price | $51.99 | 52-week high | $52.00 |
| Prev. close | $51.96 | 52-week low | $14.95 |
| Day low | $51.98 | Volume | 2,480,300 |
| Day high | $52.00 | Avg. volume | 1,681,906 |
| 50-day MA | $51.46 | Dividend yield | N/A |
| 200-day MA | $31.96 | Market Cap | 3.71B |
CCXI Stock Price Chart Interactive Chart >
ChemoCentryx, Inc. (CCXI) Company Bio
ChemoCentryx, Inc. focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company was founded in 1997 and is based in Mountain View, California.
Latest CCXI News From Around the Web
Below are the latest news stories about CHEMOCENTRYX INC that investors may wish to consider to help them evaluate CCXI as an investment opportunity.
ChemoCentryx shareholders approve $4.7B merger with Amgen
|
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephro |
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year. |
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced two upcoming poster presentations for CCX559, the Company’s investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meet |
Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
CCXI Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 13.27% |
| 5-year | 296.27% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -41.20% |
| 2020 | 56.56% |
| 2019 | 262.51% |
Continue Researching CCXI
Want to do more research on ChemoCentryx Inc's stock and its price? Try the links below:ChemoCentryx Inc (CCXI) Stock Price | Nasdaq
ChemoCentryx Inc (CCXI) Stock Quote, History and News - Yahoo Finance
ChemoCentryx Inc (CCXI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...